How Mechanical Ventilators Silently Weaken the Diaphragm and What Can Stop It
A 2025 review reveals the molecular mechanisms behind ventilator-induced diaphragm dysfunction and emerging strategies to prevent it.
Summary
Mechanical ventilation, while life-saving, can weaken the diaphragm within hours through a condition called ventilator-induced diaphragmatic dysfunction (VIDD). This 2025 review synthesizes epidemiology, pathophysiology, monitoring approaches, and emerging treatments. Key mechanisms include mitochondrial oxidative stress driving both accelerated protein breakdown and suppressed protein synthesis, alongside dysfunction in the ubiquitin-proteasome pathway, lysosomal autophagy, calpain, caspase-3, and ryanodine receptor-1 signaling. Up to 80% of patients with difficult weaning show diaphragmatic weakness. Lung- and diaphragm-protective ventilation strategies, along with antioxidant-based pharmacological interventions showing promise in animal models, represent the frontier of prevention and treatment.
Detailed Summary
Mechanical ventilation (MV) is indispensable for critically ill patients, yet even short-term use—exceeding 12 hours in animals or 18 hours in humans—can trigger ventilator-induced diaphragmatic dysfunction (VIDD): a measurable loss of diaphragm force-generating capacity and fiber atrophy directly attributable to ventilator support. VIDD is clinically significant, contributing to weaning failure in up to 35% of patients, difficult or prolonged weaning in roughly 19%, and diaphragmatic weakness in up to 80% of those who struggle to wean. Notably, diaphragmatic dysfunction occurs twice as frequently as peripheral muscle weakness during spontaneous breathing trials.
The earliest and most prominent feature of VIDD is reduced diaphragmatic contractile force, detectable within hours of MV onset. Structurally, this is accompanied by diaphragm fiber atrophy—predominantly affecting slow-twitch (type I) and fast-twitch (type IIa) fibers—and shifts in fiber-type composition. Mitochondrial oxidative stress is identified as the central upstream driver: controlled mechanical ventilation suppresses diaphragm activity, leading to reactive oxygen species (ROS) overproduction that disrupts mitochondrial dynamics (fusion/fission balance), impairs energy metabolism, and activates downstream proteolytic cascades including the ubiquitin-proteasome pathway, lysosomal autophagy, calpain, and caspase-3. Simultaneously, protein synthesis is suppressed via inhibition of the IGF-1/PI3K/Akt/mTOR anabolic signaling axis.
Respiratory mechanics play a critical macroscopic role. Both over-assistance (disuse atrophy) and under-assistance (eccentric myotrauma from excessive effort) contribute to VIDD. Patient-ventilator asynchrony, including reverse triggering and breath stacking, can impose injurious eccentric loads on the diaphragm. Monitoring tools such as diaphragm ultrasound (thickening fraction, excursion), esophageal and transdiaphragmatic pressure measurements, P0.1, and diaphragm electromyography (EMGdi) allow real-time titration of ventilatory support to a 'therapeutic window' that avoids both extremes. Advanced modes like neurally adjusted ventilatory assist (NAVA) and proportional assist ventilation (PAV+) show promise in maintaining physiological effort levels.
Pharmacological prevention strategies informed by mechanistic understanding include antioxidants (targeting mitochondrial ROS), proteasome inhibitors, autophagy modulators, and agents targeting ryanodine receptor-1 dysfunction. While results in animal models are encouraging, translation to human clinical trials remains limited, representing a key gap. Dysregulation of ryanodine receptor-1 leading to calcium leak and impaired excitation-contraction coupling is an emerging mechanism that may partly explain contractile failure independent of atrophy.
This review underscores that VIDD is not an inevitable consequence of MV but a potentially preventable condition. Integrating lung- and diaphragm-protective ventilation protocols—balancing lung protection targets with maintaining adequate diaphragm activity—alongside emerging pharmacological strategies represents the most promising path forward for improving ICU outcomes.
Key Findings
- VIDD affects up to 80% of patients with difficult weaning and develops within 12–18 hours of MV onset.
- Mitochondrial oxidative stress is the central upstream mechanism, driving both protein degradation and suppressed synthesis.
- Both over-support (disuse) and under-support (eccentric myotrauma) contribute to diaphragm injury during MV.
- Diaphragm ultrasound, esophageal pressure monitoring, and EMGdi enable real-time protective ventilation titration.
- Antioxidants and proteasome/autophagy pathway inhibitors show promise in animal models but lack human trial validation.
Methodology
This is a comprehensive narrative review published in the European Respiratory Review (2025), synthesizing evidence from animal studies, human biopsy data, clinical observational studies, and mechanistic molecular research. The authors draw on multicentre observational trials (WEAN-SAFE, WIND), experimental MV models, and emerging pharmacological and ventilation strategy literature to construct an integrated pathophysiological framework.
Study Limitations
Most pharmacological interventions demonstrating benefit (antioxidants, proteasome inhibitors) are based on animal models and have not yet been validated in large human clinical trials. The review is narrative rather than systematic or meta-analytic, which introduces potential selection bias in evidence synthesis. The molecular mechanisms of VIDD, particularly the relative contributions of individual proteolytic pathways and ryanodine receptor dysfunction, remain incompletely characterized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: